LTAS
MRNA icon

Linden Thomas Advisory Services’s Moderna MRNA Stock Holding History

Linden Thomas Advisory Services’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,918
Closed -$246K – 470
2024
Q4 		$246K Buy
5,918
+6
+0.1% +$287 0.03% 443
2024
Q3 		$395K Buy
5,912
+317
+6% +$29.1K 0.05% 396
2024
Q2 		$664K Buy
5,595
+79
+1% +$10K 0.1% 318
2024
Q1 		$588K Buy
5,516
+443
+9% +$44.7K 0.09% 330
2023
Q4 		$505K Buy
5,073
+256
+5% +$21.5K 0.09% 332
2023
Q3 		$498K Sell
4,817
-4,938
-51% -$551K 0.11% 324
2023
Q2 		$1.19M Buy
9,755
+264
+3% +$35.2K 0.26% 157
2023
Q1 		$1.46M Buy
9,491
+213
+2% +$35.1K 0.36% 103
2022
Q4 		$1.67M Buy
+9,278
New +$1.52M 0.47% 59

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Linden Thomas Advisory Services's MRNA Position: Q1 2025 in Review

Linden Thomas Advisory Services sold out of Moderna (MRNA) in Q1 2025, closing a stake of 5,918 shares — an estimated $246K sold.

Linden Thomas Advisory Services first reported a position in MRNA in Q4 2022 and held it in 9 quarters. The position peaked at $1.67M in Q4 2022. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Linden Thomas Advisory Services reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Linden Thomas Advisory Services sold 5,918 Moderna shares in Q1 2025, an estimated $246K.
  • Linden Thomas Advisory Services first reported a position in Moderna in Q4 2022 and held it in 9 quarters.
  • Linden Thomas Advisory Services's Moderna position peaked at $1.67M in Q4 2022.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Linden Thomas Advisory Services's 13F filing for Q1 2025, filed 30 Apr 2025.